![David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals](https://oncodaily.com/pub/uploads/2023/11/7C1FB216-6EFA-40EF-ACAB-0F15768F1D98.jpeg)
Photo taken from David Sebag-Montefiore/LinkedIn
Apr 1, 2024, 09:54
David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals
David Sebag, Professor of Clinical Oncology and Health Research at University of Leeds, shared on X:
“Fantastic news! Following last week’s brilliant hybrid workshop at University of Leeds, the first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals today!
Huge congrats to the team!
ARTEMIS will test the benefits of adding Adlai Nortye AN0025 to short course and long course CRT. It is a selective inhibitor of EP4, one of four PGE2 receptors, a strong pre-clinical rationale and a high CR rate in early phase.
doi: 10.1016/j.radonc.2023.109669
You can read more about this study here.”
Source: David Sebag/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023